Ondansetron(GR 38032F) is an antiemetic agent with a selective antagonistic action to serotonin S3 receptors, devoid of anti-dopaminergic property.
The effects of ondansetron in control of nausea and emesis induced by cisplatin containing chemotherapy regimen were compared to those of formerly used antiemtic agents, MDL (metoclopramide, dexamethasone, lorazepam combination) therapy.
Ondansetron was given to the patient, who had vomiting in first and second cycle of chemotherapy containing cisplatin with MDL therapy. It was administered intravenously 15 min before and 4 hours and 8 hours after cisplatin administration, then
given
orally every 12 hour up to 24 hours after end of chemotherapy. No other antiemetics were used.
Major control(complete and near complete) of emesis was achieved in 2 of 30(6.7%) patients receiving ondansetron and in 4 of 30(13.3%) patients receiving MLD. For acute emesis, major control was achieved in 24 of 30(80.0%) patients with
ondansetron. For
delayed emesis, major control was achieved in 3 of 30(10.0%) patients with ondansetron. No severe side reaction was seen in patients receiving ondansetron, while transient elevations in aspartate or alanine aminotransferase level were observed in
10
patients.
In conclusion, ondansetron was safe and effective in controlling the acute emesis, comparable to MDL therapy, but was less effective in controlling delayed emesis.
|